Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Clinical trial NCT06568367 · RECRUITING
Trial details
- NCT number
- NCT06568367
- Sponsor
- Axsome Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2026-12-01
- Enrollment
- 520
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.